Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma

Christine H. Chung, Qiang Zhang, Elizabeth M. Hammond, Andy M. Trotti, Huijun Wang, Sharon Spencer, Hua Zhong Zhang, Jay Cooper, Richard Jordan, Marvin H. Rotman, K. Kian Ang

Research output: Contribution to journalArticle

Abstract

Purpose: Epidermal growth factor receptor (EGFR) overexpression has been consistently found to be an independent predictor of local-regional relapse (LRR) after radiotherapy. We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC). Methods and Materials: EGFR expression in locally advanced HNSCC was measured by immunohistochemistry in a series of patients randomized to receive accelerated or conventional radiation regimens in a Phase III trial. Subsequently, data of the two series were pooled (N = 533) for conducting a recursive partitioning analysis that incorporated clinical parameters (e.g., performance status, primary site, T and N categories) and four molecular markers (EGFR, p53, Ki-67, and microvessel density). Results: This study confirmed that patients with higher than median levels of tumor EGFR expression had a lower OS (relative risk [RR]: 1.90, p = 0.0010) and a higher LRR (RR: 1.91, p = 0.0163). Of the four markers analyzed, only EGFR was found to contribute to refining classification of patients into three risk classes with distinct OS and LRR outcomes. The addition of EGFR to three clinical parameters could identify patients having up to a fivefold difference in the risk of LRR. Conclusions: Adding pretreatment EGFR expression data to known robust clinical prognostic variables improved the estimation of the probability for OS and LRR after radiotherapy. Its use for stratifying or selecting patients with defined tumor feature and pattern of relapse for enrollment into clinical trials testing specific therapeutic strategy warrants further investigation.

Original languageEnglish (US)
Pages (from-to)331-338
Number of pages8
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume81
Issue number2
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
cancer
Recurrence
Survival
markers
Radiotherapy
radiation therapy
tumors
Microvessels
Carcinoma, squamous cell of head and neck
refining
Neoplasms
pretreatment
Immunohistochemistry
Clinical Trials
Radiation
conduction
radiation
predictions

Keywords

  • Epidermal growth factor receptor
  • Head-and-neck squamous cell carcinoma
  • Prognosis
  • Risk classification

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. / Chung, Christine H.; Zhang, Qiang; Hammond, Elizabeth M.; Trotti, Andy M.; Wang, Huijun; Spencer, Sharon; Zhang, Hua Zhong; Cooper, Jay; Jordan, Richard; Rotman, Marvin H.; Ang, K. Kian.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 81, No. 2, 01.10.2011, p. 331-338.

Research output: Contribution to journalArticle

Chung, Christine H. ; Zhang, Qiang ; Hammond, Elizabeth M. ; Trotti, Andy M. ; Wang, Huijun ; Spencer, Sharon ; Zhang, Hua Zhong ; Cooper, Jay ; Jordan, Richard ; Rotman, Marvin H. ; Ang, K. Kian. / Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. In: International Journal of Radiation Oncology, Biology, Physics. 2011 ; Vol. 81, No. 2. pp. 331-338.
@article{0249f544171d453d8aa500042122a908,
title = "Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma",
abstract = "Purpose: Epidermal growth factor receptor (EGFR) overexpression has been consistently found to be an independent predictor of local-regional relapse (LRR) after radiotherapy. We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC). Methods and Materials: EGFR expression in locally advanced HNSCC was measured by immunohistochemistry in a series of patients randomized to receive accelerated or conventional radiation regimens in a Phase III trial. Subsequently, data of the two series were pooled (N = 533) for conducting a recursive partitioning analysis that incorporated clinical parameters (e.g., performance status, primary site, T and N categories) and four molecular markers (EGFR, p53, Ki-67, and microvessel density). Results: This study confirmed that patients with higher than median levels of tumor EGFR expression had a lower OS (relative risk [RR]: 1.90, p = 0.0010) and a higher LRR (RR: 1.91, p = 0.0163). Of the four markers analyzed, only EGFR was found to contribute to refining classification of patients into three risk classes with distinct OS and LRR outcomes. The addition of EGFR to three clinical parameters could identify patients having up to a fivefold difference in the risk of LRR. Conclusions: Adding pretreatment EGFR expression data to known robust clinical prognostic variables improved the estimation of the probability for OS and LRR after radiotherapy. Its use for stratifying or selecting patients with defined tumor feature and pattern of relapse for enrollment into clinical trials testing specific therapeutic strategy warrants further investigation.",
keywords = "Epidermal growth factor receptor, Head-and-neck squamous cell carcinoma, Prognosis, Risk classification",
author = "Chung, {Christine H.} and Qiang Zhang and Hammond, {Elizabeth M.} and Trotti, {Andy M.} and Huijun Wang and Sharon Spencer and Zhang, {Hua Zhong} and Jay Cooper and Richard Jordan and Rotman, {Marvin H.} and Ang, {K. Kian}",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2010.05.024",
language = "English (US)",
volume = "81",
pages = "331--338",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma

AU - Chung, Christine H.

AU - Zhang, Qiang

AU - Hammond, Elizabeth M.

AU - Trotti, Andy M.

AU - Wang, Huijun

AU - Spencer, Sharon

AU - Zhang, Hua Zhong

AU - Cooper, Jay

AU - Jordan, Richard

AU - Rotman, Marvin H.

AU - Ang, K. Kian

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Purpose: Epidermal growth factor receptor (EGFR) overexpression has been consistently found to be an independent predictor of local-regional relapse (LRR) after radiotherapy. We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC). Methods and Materials: EGFR expression in locally advanced HNSCC was measured by immunohistochemistry in a series of patients randomized to receive accelerated or conventional radiation regimens in a Phase III trial. Subsequently, data of the two series were pooled (N = 533) for conducting a recursive partitioning analysis that incorporated clinical parameters (e.g., performance status, primary site, T and N categories) and four molecular markers (EGFR, p53, Ki-67, and microvessel density). Results: This study confirmed that patients with higher than median levels of tumor EGFR expression had a lower OS (relative risk [RR]: 1.90, p = 0.0010) and a higher LRR (RR: 1.91, p = 0.0163). Of the four markers analyzed, only EGFR was found to contribute to refining classification of patients into three risk classes with distinct OS and LRR outcomes. The addition of EGFR to three clinical parameters could identify patients having up to a fivefold difference in the risk of LRR. Conclusions: Adding pretreatment EGFR expression data to known robust clinical prognostic variables improved the estimation of the probability for OS and LRR after radiotherapy. Its use for stratifying or selecting patients with defined tumor feature and pattern of relapse for enrollment into clinical trials testing specific therapeutic strategy warrants further investigation.

AB - Purpose: Epidermal growth factor receptor (EGFR) overexpression has been consistently found to be an independent predictor of local-regional relapse (LRR) after radiotherapy. We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC). Methods and Materials: EGFR expression in locally advanced HNSCC was measured by immunohistochemistry in a series of patients randomized to receive accelerated or conventional radiation regimens in a Phase III trial. Subsequently, data of the two series were pooled (N = 533) for conducting a recursive partitioning analysis that incorporated clinical parameters (e.g., performance status, primary site, T and N categories) and four molecular markers (EGFR, p53, Ki-67, and microvessel density). Results: This study confirmed that patients with higher than median levels of tumor EGFR expression had a lower OS (relative risk [RR]: 1.90, p = 0.0010) and a higher LRR (RR: 1.91, p = 0.0163). Of the four markers analyzed, only EGFR was found to contribute to refining classification of patients into three risk classes with distinct OS and LRR outcomes. The addition of EGFR to three clinical parameters could identify patients having up to a fivefold difference in the risk of LRR. Conclusions: Adding pretreatment EGFR expression data to known robust clinical prognostic variables improved the estimation of the probability for OS and LRR after radiotherapy. Its use for stratifying or selecting patients with defined tumor feature and pattern of relapse for enrollment into clinical trials testing specific therapeutic strategy warrants further investigation.

KW - Epidermal growth factor receptor

KW - Head-and-neck squamous cell carcinoma

KW - Prognosis

KW - Risk classification

UR - http://www.scopus.com/inward/record.url?scp=80052788509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052788509&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.05.024

DO - 10.1016/j.ijrobp.2010.05.024

M3 - Article

VL - 81

SP - 331

EP - 338

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -